Moderna Drops 7.8% as Outbreak Concerns Ease

• Our read: Moderna Inc sits in the weakest quality tier with an E grade against large-cap Healthcare peers, where price trend contrasts with persistent vulnerabilities in efficiency.
• The day: The shares fell 7.8% to $187.46 as health officials eased outbreak concerns and investors locked in gains ahead of clinical trial data.
• Watching: The next quarterly earnings report scheduled for Thursday, November 5.

Shares of Moderna Inc fell 7.8% to close at $187.46 on Tuesday, with trading volume reaching 1.3x the 20-session average. The decline reversed Monday's advance after a World Health Organization official stated that the risk of a plague epidemic was low, deflating a brief rise across vaccine developers following an isolated death at a research institute in Siberia.

The pullback also reflected profit-taking following an extended rally. The stock had advanced on news of its upcoming addition to the Nasdaq-100 and continued optimism for its Phase 3 melanoma program partnered with Merck. With the full clinical trial readout scheduled for presentation at a medical conference later this month, some market participants chose to reduce exposure ahead of the event.

Tuesday's decline interrupted a substantial multi-month advance. Even with the pullback, the shares are +28.8% over the past month and +535.7% so far this year.

Moderna Inc carried an E grade from EasyAlpha into Tuesday's session against its industry peers among Healthcare companies in the S&P 500. Companies graded A or B have stronger fundamentals, and historically they have carried a lower risk of large drawdowns than companies graded D or E. While price trend is its primary strength, efficiency remains the key area to watch.

Wall Street analysts have maintained a skeptical stance during the advance. Of the 23 analysts covering the company, only 21.7% issue a buy rating. The consensus price target of $120.67 sits 35.6% below Tuesday's close.